Huge trial on our core work, catch-up here
The CONVINCE Visual Abstract
Check out the COVINCE-ing Visual Abstract by Saumya Vishnoi
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
Huge trial on our core work, catch-up here
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) July 31, 2023
✳️10 tweets #NephJC catch-up ✳️
🌟Let’s recap the CONVINCE trial which pitted HDF against HD
🌟Do we now have CONVINCE-ing evidence for the superiority of convection added to diffusion? pic.twitter.com/92gW0zKv76
Check out the COVINCE-ing Visual Abstract by Saumya Vishnoi